Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections

NCT02687906 is registered in ClinicalTrials.gov with Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) as lead sponsor.

NCT NCT02687906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02687906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2016
Completion date
July 15, 2026
Enrollment
39 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infections